Literature DB >> 34650297

[Clinical features of patients with Rhupus syndrome].

Z F Li1, X Wu1, L J Wu1, C N Luo1, Y M Shi1, Y Zhong1, X M Chen1, X Y Meng1.   

Abstract

OBJECTIVE: To investigate the clinical and serological features of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) overlap syndrome (Rhupus syndrome).
METHODS: We retrospectively reviewed the medical records of 21 patients with Rhupus syndrome who were hospitalized at Department of Rheumatology and Immunology, People's Hospital of Xinjiang Uygur Autonomous Region between January 2010 and January 2018. We compared the joint involvement, autoantibodies and clinical manifestations of Rhupus syndrome with 81 cases of RA-alone and 51 cases of SLE-alone.
RESULTS: In 21 patients with Rhupus syndrome, there are 3 males and 18 females. Compared with the SLE-alone group, the patients with Rhupus syndrome were older [(49.43±11.66) vs. (40.59±12.73), P=0.008]. The median age of the patients with Rhupus syndrome at RA onset was significantly younger than that of the RA-alone patients [(32.58±11.14) vs. (43.11±11.83), P=0.010]. Of the 21 patients with Rhupus syndrome, the initial diagnosis was RA in 57% (12/21), except 2 male patients, the other 10 patients with SLE manifestations were menopause, the mean age of amenorrhea or menopause was (44.30±5.33) (36-50) years. The mean interval between the onset of SLE and RA was 10.83 years. Two patients started with SLE manifestations. Moreover, both diseases simultaneously developed in 33.3% of the patients. Except one male patient, 3 patients were in menopause stage when RA and SLE appeared. The positive rate of specific antibody Rhupus syndrome was similar to that of RA. Renal damage was relatively rare in SLE related manifestations, but the incidence of interstitial lung disease was higher. There were no significant differences in the prevalence of complements C3 and C4, antinuclear antibody (ANA), anti-double-stranded DNA (anti-dsDNA), anti-SSA or anti-SSB antibody between the Rhupus syndrome and SLE-alone group.
CONCLUSION: Rhupus syndrome is an overlapping syndrome in which RA and SLE coexist. Most of the diseases occur in RA and the related manifestations of RA are more serious than those of SLE. The incidence of Rhupus syndrome may be related to the change of sex hormone levels.

Entities:  

Keywords:  Arthritis, rheumatoid; Lupus Erythematosus, systemic; Rhupus syndrome

Mesh:

Substances:

Year:  2021        PMID: 34650297      PMCID: PMC8517678     

Source DB:  PubMed          Journal:  Beijing Da Xue Xue Bao Yi Xue Ban        ISSN: 1671-167X


  18 in total

1.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

2.  Clinical and laboratory profiles of rhupus syndrome in a Chinese population: a single-centre study of 51 patients.

Authors:  T Liu; G Li; R Mu; H Ye; W Li; Z Li
Journal:  Lupus       Date:  2014-03-07       Impact factor: 2.911

3.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

Authors:  F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra
Journal:  Arthritis Rheum       Date:  1988-03

4.  Rhupus syndrome: assessment of its prevalence and its clinical and instrumental characteristics in a prospective cohort of 103 SLE patients.

Authors:  C Tani; D D'Aniello; A Delle Sedie; L Carli; M Cagnoni; N Possemato; M Carbone; A Della Rossa; L Riente; C Baldini; R Talarico; D Caramella; S Bombardieri; M Mosca
Journal:  Autoimmun Rev       Date:  2012-10-11       Impact factor: 9.754

5.  Clinical and immunogenetic characterization of Mexican patients with 'rhupus'.

Authors:  J A Simón; J Granados; J Cabiedes; J Ruíz Morales; J Alcocer Varela
Journal:  Lupus       Date:  2002       Impact factor: 2.911

6.  Rituximab treatment for 'rhupus syndrome': clinical and power-Doppler ultrasonographic monitoring of response. A longitudinal pilot study.

Authors:  M Piga; A Gabba; A Cauli; P Garau; A Vacca; A Mathieu
Journal:  Lupus       Date:  2013-04-04       Impact factor: 2.911

7.  The classification of glomerulonephritis in systemic lupus erythematosus revisited.

Authors:  Jan J Weening; Vivette D D'Agati; Melvin M Schwartz; Surya V Seshan; Charles E Alpers; Gerald B Appel; James E Balow; Jan A Bruijn; Terence Cook; Franco Ferrario; Agnes B Fogo; Ellen M Ginzler; Lee Hebert; Gary Hill; Prue Hill; J Charles Jennette; Norella C Kong; Philippe Lesavre; Michael Lockshin; Lai-Meng Looi; Hirofumi Makino; Luiz A Moura; Michio Nagata
Journal:  J Am Soc Nephrol       Date:  2004-02       Impact factor: 10.121

8.  Presence of antibodies against cyclic citrullinated peptides in patients with 'rhupus': a cross-sectional study.

Authors:  Luis M Amezcua-Guerra; Rashidi Springall; Ricardo Marquez-Velasco; Lorena Gómez-García; Angélica Vargas; Rafael Bojalil
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

9.  Clinical analysis of 56 patients with rhupus syndrome: manifestations and comparisons with systemic lupus erythematosus: a retrospective case-control study.

Authors:  Jing Li; Honghua Wu; Xinxiang Huang; Dong Xu; Wenjie Zheng; Yan Zhao; Wanli Liu; Xiaofeng Zeng
Journal:  Medicine (Baltimore)       Date:  2014-08       Impact factor: 1.889

10.  Efficacy of abatacept for arthritis in patients with an overlap syndrome between rheumatoid arthritis and systemic lupus erythematosus.

Authors:  Kei Ikeda; Yoshie Sanayama; Sohei Makita; Junichi Hosokawa; Mieko Yamagata; Daiki Nakagomi; Katsuhiko Takabayashi; Hiroshi Nakajima
Journal:  Clin Dev Immunol       Date:  2013-11-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.